AACR 2023: Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution

AACR 2023: Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution

Used in the poster: B-NDG MGMT3 mice

Conclusions

  • We generated an immunodeficient (B-NDG) mouse model containing human GM-CSF, CSF1, THPO, and IL3 in place of the murine counter-parts. Human GM-CSF, CSF1 and THPO proteins were detected in B-NDG MGMT3 mice. As B-NDG mice lack mature T cells, IL3 was not detected.
  • The survival rate of B-NDG MGMT3 mice after human CD34+ HSC engraftment was similar to that of B-NDG mice until 18 weeks post-engraftment.
  • The proportion of CD45+ cells in B-NDG MGMT3 mice reached 25% after 12 weeks post-engraftment and continued to rise higher than levels observed in B-NDG mice. The proportion and number of monocytes, MDSCs, DCs and Tregs in B-NDG MGMT3 mice were also higher in B-NDG MGMT3 mice compared to B-NDG mice.
  • B-NDG MGMT3 mice are a novel humanized model for human myeloid and lymphocytic cell reconstitution that does not require preconditioning.

Share:

    Please fill out the form below to request a download of this poster